PTC Therapeutics debuts new gene therapy manufacturing facility

PTC Therapeutics, Inc., a biopharma company, has opened a new gene therapy manufacturing facility in Hopewell, NJ, its second location in the state. The additional location—in South Plainfield—is designated as the firm’s global headquarters.

PTC's Hopewell facility, which will complement the aforementioned HQ, consists of approximately 220,500 square feet of office, manufacturing and laboratory space, including technology that is prepared to handle process development and manufacturing of plasmids and adeno-associated virus (AAV) vectors. The company is also providing plasmid DNA and AAV manufacturing services to external partners.

According to company officials, PTC's in-house manufacturing, research and development abilities support control over the quality, capacity, supply and shift from clinical to commercial development.

" … Gene therapy holds tremendous promise to treat intractable rare genetic disorders,” says Stuart W. Peltz, PhD, CEO of PTC Therapeutics. “We have built our capabilities to both perform gene therapy research and to manufacture these biological products. We are proud to have such a talented team and state-of-the-art manufacturing facility here in Hopewell, NJ that will help expedite bringing these therapies to patients."